Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 3, 2017BloodOpen Access

Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

BPBarbara ProColumbia University Irving Medical CenterRARanjana H. AdvaniRutgers, The State University of New JerseyPBPauline BriceUniversité Claude Bernard Lyon 1

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Pro et al. (2017) studied this question.

synapsesocial.com/papers/69d97e215e5bcb4e3b836d59https://doi.org/10.1182/blood-2017-05-780049
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Microtubule-Depolymerizing Agents Used in Antibody–Drug Conjugates Induce Antitumor Immunity by Stimulation of Dendritic Cells2014 · 202 citations
  2. 2Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study2011 · 654 citations
  3. 3ALK− anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project2008 · 867 citations
  4. 4Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-302007 · 119 citations
  5. 5Graft-Versus-Lymphoma Effect for Aggressive T-Cell Lymphomas in Adults: A Study by the Société Française de Greffe de Moëlle et de Thérapie Cellulaire2008 · 295 citations